Nabriva Therapeutics AG - Company Profile (NASDAQ:NBRV)

About Nabriva Therapeutics AG -

Nabriva Therapeutics AG - logoNabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Two plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs). In addition, the Company has completed a Phase Two clinical trial for acute bacterial skin and skin structure infections (ABSSSI) and in Discovery Phase development of extended-spectrum pleuromutilins (ESPs), a pleuromutilin compound that treats Gram-negative bacteria. The Company is a spin-off of Sandoz GmbH and receives investment from HBM Healthcare Investments, Novartis Venture Fund, Omega Funds, OrbiMed Healthcare Fund Management, Phase4 Partners, Vivo Capital and the Wellcome Trust.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NBRV
  • CUSIP:
Key Metrics:
  • Previous Close: $7.49
  • 50 Day Moving Average: $7.81
  • 200 Day Moving Average: $8.20
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.98
  • P/E Growth: 0.00
  • Market Cap: $159.21M
  • Outstanding Shares: 21,257,000
Additional Links:
Companies Related to Nabriva Therapeutics AG -:

Analyst Ratings

Consensus Ratings for Nabriva Therapeutics AG - (NASDAQ:NBRV) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $17.40 (132.31% upside)

Analysts' Ratings History for Nabriva Therapeutics AG - (NASDAQ:NBRV)
Show:
DateFirmActionRatingPrice TargetDetails
8/9/2016WedbushReiterated RatingOutperform$17.00View Rating Details
1/27/2016GabelliInitiated CoverageBuy$14.00View Rating Details
11/12/2015Needham & Company LLCReiterated RatingBuy$15.00View Rating Details
11/12/2015Royal Bank Of CanadaBoost Price TargetOutperform$21.00 -> $22.00View Rating Details
10/13/2015Leerink SwannInitiated CoverageOutperform$10.00 -> $19.00View Rating Details
(Data available from 8/30/2014 forward)

Earnings

Earnings History for Nabriva Therapeutics AG - (NASDAQ:NBRV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2016        
8/9/2016($6.25)($0.50)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Nabriva Therapeutics AG - (NASDAQ:NBRV)
Current Year EPS Consensus Estimate: $-1.90 EPS
Next Year EPS Consensus Estimate: $-2.51 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.55)($0.55)($0.55)
Q2 20161($0.58)($0.58)($0.58)
Q3 20161($0.50)($0.50)($0.50)
Q4 20161($0.10)($0.10)($0.10)
Q1 20171($0.18)($0.18)($0.18)
Q2 20171($0.18)($0.18)($0.18)
Q3 20171($0.18)($0.18)($0.18)
Q4 20171($0.09)($0.09)($0.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Nabriva Therapeutics AG - (NASDAQ:NBRV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Nabriva Therapeutics AG - (NASDAQ:NBRV)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Nabriva Therapeutics AG - (NASDAQ:NBRV)
DateHeadline
finance.yahoo.com logoNabriva to Present at the 2016 Wedbush PacGrow Healthcare Conference (NASDAQ:NBRV)
finance.yahoo.com - August 10 at 9:29 AM
publicnow.com logoNabriva Reports Second Quarter 2016 Financial Results (NASDAQ:NBRV)
www.publicnow.com - August 9 at 9:35 AM
publicnow.com logoNabriva Announces Nomination of Candidates for Its Supervisory Board (NASDAQ:NBRV)
www.publicnow.com - July 25 at 7:28 AM
fxpips.com logoMost Advanced Stocks on NASDAQ (NASDAQ:NBRV)
www.fxpips.com - July 20 at 9:18 AM
finance.yahoo.com logoF2G Ltd Announces the Appointment of Ralf Schmid to the Position of Chief Financial Officer (NASDAQ:NBRV)
finance.yahoo.com - July 11 at 4:00 AM
publicnow.com logoNabriva to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference (NASDAQ:NBRV)
www.publicnow.com - July 5 at 7:21 AM
nasdaq.com logoEuropean ADRs Marginally Higher as Healthcare Stocks See Mixed Fortunes (NASDAQ:NBRV)
www.nasdaq.com - July 1 at 6:23 PM
nasdaq.com logoNabriva Presents Data on Lefamulin at the American Society of Microbiology (ASM) Microbe 2016 Conference (NASDAQ:NBRV)
www.nasdaq.com - June 20 at 6:16 PM
publicnow.com logoNabriva to Present at the JMP Securities Life Sciences Conference (NASDAQ:NBRV)
www.publicnow.com - June 14 at 7:19 AM
capitalcube.com logoNabriva Therapeutics AG :NBRV-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 (NASDAQ:NBRV)
www.capitalcube.com - June 6 at 2:31 PM
marketwatch.com logoNabriva Therapeutics AG (US: NBRV) to Ring The Nasdaq Stock Market Closing Bell (NASDAQ:NBRV)
www.marketwatch.com - June 1 at 6:52 PM
publicnow.com logoNabriva Therapeutics AG (Nasdaq: NBRV) to Ring The Nasdaq Stock Market Closing Bell (NASDAQ:NBRV)
www.publicnow.com - May 31 at 10:22 AM
publicnow.com logoNabriva Announces Lefamulin Presentation at ASM Microbe 2016 Conference (NASDAQ:NBRV)
www.publicnow.com - May 16 at 7:32 AM
publicnow.com logoNabriva to Present at the UBS Global Healthcare Conference (NASDAQ:NBRV)
www.publicnow.com - May 11 at 7:22 AM
publicnow.com logoNabriva Reports First Quarter 2016 Financial Results (NASDAQ:NBRV)
www.publicnow.com - May 10 at 7:18 AM
finance.yahoo.com logoNABRIVA THERAPEUTICS AG Financials (NASDAQ:NBRV)
finance.yahoo.com - May 5 at 1:04 PM
publicnow.com logoNabriva Appoints Gary Sender as Chief Financial Officer (NASDAQ:NBRV)
www.publicnow.com - May 2 at 7:10 AM
finance.yahoo.com logo7:00 am Nabriva Therapeutics appoints Gary Sender as CFO, effective immediately (NASDAQ:NBRV)
finance.yahoo.com - May 2 at 7:00 AM
biz.yahoo.com logoNabriva Therapeutics AG Earnings Call scheduled for 8:30 am ET today (NASDAQ:NBRV)
biz.yahoo.com - April 27 at 8:30 AM
publicnow.com logoNabriva Therapeutics AG Reports Full Year 2015 Financial Results and Provides Development Update (NASDAQ:NBRV)
www.publicnow.com - April 27 at 7:21 AM
biz.yahoo.com logoQ4 2015 Nabriva Therapeutics AG Earnings Release - Before Market Open (NASDAQ:NBRV)
biz.yahoo.com - April 27 at 7:07 AM
publicnow.com logoNabriva Therapeutics AG to Provide Development Update and Announce Full Year 2015 Financial Results; Conference Call on Wednesday, April 27, 2016 (NASDAQ:NBRV)
www.publicnow.com - April 19 at 7:15 AM
marketexclusive.com logoNabriva Therapeutics (NASDAQ:NBRV) Initiates 2nd Phase III Trials of Lefamulin (NASDAQ:NBRV)
marketexclusive.com - April 15 at 12:10 PM
publicnow.com logoNabriva Initiates Second Phase 3 Clinical Trial of Lefamulin (“LEAP 2”) in Patients with Community-Acquired Bacterial Pneumonia (CABP) (NASDAQ:NBRV)
www.publicnow.com - April 11 at 8:20 AM
publicnow.com logoNabriva Therapeutics AG to Present at the 15th Annual Needham Healthcare Conference (NASDAQ:NBRV)
www.publicnow.com - April 5 at 7:17 AM
bilbaoya.com logoAverage Rating Watch Nabriva Therapeutics AG - ADR (NASDAQ:NBRV) (NASDAQ:NBRV)
bilbaoya.com - March 31 at 10:53 AM
wsj.com logo[$$] Iterum Therapeutics Secures $40M Series A, Licenses Anti-Infective Drug (NASDAQ:NBRV)
www.wsj.com - March 28 at 9:07 AM
finance.yahoo.com logoNabriva Therapeutics AG to Participate in Two Investor Conferences in February (NASDAQ:NBRV)
finance.yahoo.com - February 3 at 7:00 AM
finance.yahoo.com logoCoverage initiated on Nabriva Therapeutics by Gabelli & Co (NASDAQ:NBRV)
finance.yahoo.com - January 27 at 9:07 AM
finance.yahoo.com logoNabriva Therapeutics AG (NBRV) (NASDAQ:NBRV)
finance.yahoo.com - January 21 at 8:56 AM
insidermonkey.com logoDo Hedge Funds Love Lawson Products, Inc. (LAWS)? (NASDAQ:NBRV)
www.insidermonkey.com - November 27 at 9:42 AM
noodls.com logoNabriva Therapeutics AG Provides Development Update and Reports Nine Month 2015 Financial Results (NASDAQ:NBRV)
www.noodls.com - November 11 at 7:26 AM
biz.yahoo.com logoQ3 2015 Nabriva Therapeutics AG Earnings Release - Before Market Open (NASDAQ:NBRV)
biz.yahoo.com - November 11 at 7:07 AM
noodls.com logoNabriva Therapeutics AG to Provide Development Update and Announce Nine Month 2015 Financial Results; Conference Call on Wednesday, November 11, 2015 (NASDAQ:NBRV)
www.noodls.com - November 4 at 7:27 AM
insidermonkey.com logoThese Two Healthcare Stocks Receive A Vote Of Confidence From Elite Hedge Fund Managers (NASDAQ:NBRV)
www.insidermonkey.com - October 5 at 12:57 PM
noodls.com logoNabriva Therapeutics Announces Closing of Its Initial Public Offering (NASDAQ:NBRV)
www.noodls.com - September 23 at 4:35 PM
noodls.com logoNabriva Therapeutics Prices Initial Public Offering (NASDAQ:NBRV)
www.noodls.com - September 21 at 2:05 PM
noodls.com logoInitial Public Offering of Nabriva Therapeutics (NASDAQ:NBRV)
www.noodls.com - September 21 at 12:35 AM
247wallst.com logoIPO Calendar Shows 3 Offerings on Tap for the Coming Week (NASDAQ:NBRV)
247wallst.com - September 20 at 9:38 AM
investors.com logoIPO Stock Watch: Regenxbio Jumps On First Trading Day (NASDAQ:NBRV)
news.investors.com - September 17 at 4:20 PM
investors.com logoRegenxbio Turns In Strong, Upsized IPO Performance (NASDAQ:NBRV)
news.investors.com - September 16 at 6:22 PM

Social

Nabriva Therapeutics AG - (NASDAQ:NBRV) Chart for Tuesday, August, 30, 2016


Last Updated on 8/30/2016 by MarketBeat.com Staff